An overarching theme of the second Trump administration’s relationship with Congress has been forging ahead without pausing to let lawmakers weigh in. That dynamic has proven out at an agency that is responsible for regulating 20 percent of the economy: the Food and Drug Administration.
Despite its typically low profile, the FDA has had a turbulent year.
Since President Donald Trump took office, the agency has lost about 20 percent of its staff through reduction-in-force efforts, faced a mass exodus of senior leaders that usually remain after an administration change, and has had a hand in major changes to U.S. vaccine policy.
